The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
Breakdown
- Lenacapavir, a twice-yearly HIV prevention injection, approved in the EU. 21s
- The drug offers 99.9% efficacy and is an alternative to daily tablets. 4s
- Annual cost per patient could exceed $28,000, raising affordability concerns. 55s
- Gilead has agreements to provide low-cost versions in 120 low-income countries. 1m 22s
- WHO estimates 10 million people need HIV prevention drugs to reduce infections. 1m 36s